
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
September 17th, 2024
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
September 17th, 2024
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
September 4th, 2024
Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I
August 23rd, 2024
Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I
August 19th, 2024
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
August 8th, 2024
Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024
August 7th, 2024
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
July 29th, 2024
Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability
July 25th, 2024
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
July 18th, 2024